Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.
Exogenously administered tumor necrosis factor-alpha (TNF) and bacterial endotoxin (LPS) induce shock and tissue injury. Here, the authors studied the effect of endogenous TNF on LPS-induced hypotension and tissue injury and investigated the role of PAF in these responses. Rats were primed with intraperitoneal injection of zymosan 24 hours before, or Bacillus Calmette-Guérin (BCG) 12 to 15 days before intravenous injection of low dose (0.5 mg/kg) LPS. It was found that nonprimed animals showed mild hypotension and moderate leukopenia in response to LPS. In contrast, zymosanprimed rats developed shock and marked leukopenia, and more severe bowel injury than nonprimed rats. The authors then showed that, following LPS injection, zymosan-primed animals had higher TNF and platelet-activating factor (PAF) levels than nonprimed rats. Pretreatment of the animal with PAF antagonist, SRI 63-441, markedly ameliorated the hypotension and tissue injury. Interestingly, BCG-primed rats did not show aggravation of LPS-induced hypotension. Only TNF (but not PAF) level in these animals was increased. Thus, it appears that TNF release alone, without a sufficient increase in PAF, is incapable of causing severe hypotension. However, most of the BCG-primed animals showed tissue injury, which could be prevented by pretreatment with PAF antagonist. The authors discuss the possible mechanisms of this discrepancy between systemic and local responses in BCG-primed animals.
Sun
X M
XM
Department of Pathology, Children's Memorial Hospital, Northwestern University, Evanston, Illinois.
Hsueh
W
W
Torre-Amione
G
G
D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage; D004731:Endotoxins / Q000633:toxicity*; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000473:pathology; D007022:Hypotension / Q000139:chemically induced; D008070:Lipopolysaccharides / Q000633:toxicity*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D011806:Quinolinium Compounds / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012772:Shock, Septic / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000494:pharmacology*; D015054:Zymosan / Q000008:administration & dosage
D001500:BCG Vaccine; D004731:Endotoxins; D008070:Lipopolysaccharides; D010972:Platelet Activating Factor; D011806:Quinolinium Compounds; D014409:Tumor Necrosis Factor-alpha; C050531:SRI 63-441; D015054:Zymosan